Published in J Pharmacol Exp Ther on March 17, 2010
8-Hydroxyquinolines: a review of their metal chelating properties and medicinal applications. Drug Des Devel Ther (2013) 0.97
Neuroprotective and neurorestorative potential of propargylamine derivatives in ageing: focus on mitochondrial targets. J Neural Transm (Vienna) (2015) 0.83
Iron-chelating backbone coupled with monoamine oxidase inhibitory moiety as novel pluripotential therapeutic agents for Alzheimer's disease: a tribute to Moussa Youdim. J Neural Transm (Vienna) (2011) 0.79
Brain catalase in the streptozotocin-rat model of sporadic Alzheimer's disease treated with the iron chelator-monoamine oxidase inhibitor, M30. J Neural Transm (Vienna) (2014) 0.78
Effects of novel neuroprotective and neurorestorative multifunctional drugs on iron chelation and glucose metabolism. J Neural Transm (Vienna) (2012) 0.78
Inhibition of caspase-9 aggravates acute liver injury through suppression of cytoprotective autophagy. Sci Rep (2016) 0.76
M30 Antagonizes Indoleamine 2,3-Dioxygenase Activation and Neurodegeneration Induced by Corticosterone in the Hippocampus. PLoS One (2016) 0.75
Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci (2004) 5.37
PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease. Sci Transl Med (2010) 3.48
Childhood obesity. J Clin Endocrinol Metab (2004) 2.29
Increased prevalence of microvascular complications in type 2 diabetes patients with the metabolic syndrome. Isr Med Assoc J (2006) 1.60
High frequency of pre-diabetes, undiagnosed diabetes and metabolic syndrome among overweight Arabs in Israel. Isr Med Assoc J (2005) 1.57
Neurological mechanisms of green tea polyphenols in Alzheimer's and Parkinson's diseases. J Nutr Biochem (2004) 1.43
The relevance of iron in the pathogenesis of Parkinson's disease. Ann N Y Acad Sci (2004) 1.42
Role of iron in neurodegenerative disorders. Top Magn Reson Imaging (2006) 1.40
Prevention of type 1A diabetes: update. Isr Med Assoc J (2004) 1.38
Catechin polyphenols: neurodegeneration and neuroprotection in neurodegenerative diseases. Free Radic Biol Med (2004) 1.34
Involvement of protein kinase C activation and cell survival/ cell cycle genes in green tea polyphenol (-)-epigallocatechin 3-gallate neuroprotective action. J Biol Chem (2002) 1.30
Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases. Bioorg Med Chem (2005) 1.27
The relevance of iron in the pathogenesis of Parkinson's disease. J Neurochem (2011) 1.26
Cell signaling pathways in the neuroprotective actions of the green tea polyphenol (-)-epigallocatechin-3-gallate: implications for neurodegenerative diseases. J Neurochem (2004) 1.24
Gene expression profiling of sporadic Parkinson's disease substantia nigra pars compacta reveals impairment of ubiquitin-proteasome subunits, SKP1A, aldehyde dehydrogenase, and chaperone HSC-70. Ann N Y Acad Sci (2005) 1.23
Multifunctional activities of green tea catechins in neuroprotection. Modulation of cell survival genes, iron-dependent oxidative stress and PKC signaling pathway. Neurosignals (2005) 1.21
Green tea catechins as brain-permeable, natural iron chelators-antioxidants for the treatment of neurodegenerative disorders. Mol Nutr Food Res (2006) 1.21
Metallocorroles as cytoprotective agents against oxidative and nitrative stress in cellular models of neurodegeneration. J Neurochem (2010) 1.19
Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives. Brain Res Brain Res Rev (2005) 1.17
Improvement of islet function in a bioartificial pancreas by enhanced oxygen supply and growth hormone releasing hormone agonist. Proc Natl Acad Sci U S A (2012) 1.14
A molecular signature in blood identifies early Parkinson's disease. Mol Neurodegener (2012) 1.13
Targeting multiple neurodegenerative diseases etiologies with multimodal-acting green tea catechins. J Nutr (2008) 1.12
Neuroprotective molecular mechanisms of (-)-epigallocatechin-3-gallate: a reflective outcome of its antioxidant, iron chelating and neuritogenic properties. Genes Nutr (2009) 1.12
Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. Prog Neurobiol (2010) 1.11
Attenuation of 6-hydroxydopamine (6-OHDA)-induced nuclear factor-kappaB (NF-kappaB) activation and cell death by tea extracts in neuronal cultures. Biochem Pharmacol (2002) 1.10
Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine. FASEB J (2005) 1.09
Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. J Neurosci Res (2004) 1.08
Glyceraldehyde-3-phosphate dehydrogenase-monoamine oxidase B-mediated cell death-induced by ethanol is prevented by rasagiline and 1-R-aminoindan. Neurotox Res (2009) 1.04
Cell signaling pathways and iron chelation in the neurorestorative activity of green tea polyphenols: special reference to epigallocatechin gallate (EGCG). J Alzheimers Dis (2008) 1.04
Enhanced oxygen supply improves islet viability in a new bioartificial pancreas. Cell Transplant (2012) 1.03
Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats. Neuropharmacology (2004) 1.03
Neuroprotective and neuritogenic activities of novel multimodal iron-chelating drugs in motor-neuron-like NSC-34 cells and transgenic mouse model of amyotrophic lateral sclerosis. FASEB J (2009) 1.03
Simultaneous manipulation of multiple brain targets by green tea catechins: a potential neuroprotective strategy for Alzheimer and Parkinson diseases. CNS Neurosci Ther (2008) 1.02
Neuroprotective strategies in Parkinson's disease : an update on progress. CNS Drugs (2003) 1.02
Multifunctional drugs with different CNS targets for neuropsychiatric disorders. J Neurochem (2006) 0.99
Striatal dopa and glucose metabolism in PD patients with freezing of gait. Mov Disord (2006) 0.99
Redox imbalance. Cell Tissue Res (2004) 0.98
Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members. FASEB J (2004) 0.98
Manganese corroles prevent intracellular nitration and subsequent death of insulin-producing cells. ACS Chem Biol (2009) 0.98
Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci Lett (2004) 0.97
A novel role for glyceraldehyde-3-phosphate dehydrogenase and monoamine oxidase B cascade in ethanol-induced cellular damage. Biol Psychiatry (2009) 0.97
Targeting dysregulation of brain iron homeostasis in Parkinson's disease by iron chelators. Free Radic Biol Med (2013) 0.95
Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators. FASEB J (2007) 0.95
Iron-binding characteristics of neuromelanin of the human substantia nigra. Biochem Pharmacol (2003) 0.95
Therapeutic targets and potential of the novel brain- permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer's disease. J Neurochem (2006) 0.95
A novel approach of proteomics and transcriptomics to study the mechanism of action of the antioxidant-iron chelator green tea polyphenol (-)-epigallocatechin-3-gallate. Free Radic Biol Med (2007) 0.95
Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan. J Neurochem (2002) 0.94
Understanding the broad-spectrum neuroprotective action profile of green tea polyphenols in aging and neurodegenerative diseases. J Alzheimers Dis (2011) 0.93
Neuroprotective multifunctional iron chelators: from redox-sensitive process to novel therapeutic opportunities. Antioxid Redox Signal (2010) 0.93
Binding preference of p62 towards LC3-ll during dopaminergic neurotoxin-induced impairment of autophagic flux. Autophagy (2011) 0.92
cDNA gene expression profile homology of antioxidants and their antiapoptotic and proapoptotic activities in human neuroblastoma cells. FASEB J (2003) 0.92
Iron dysregulation in Alzheimer's disease: multimodal brain permeable iron chelating drugs, possessing neuroprotective-neurorescue and amyloid precursor protein-processing regulatory activities as therapeutic agents. Prog Neurobiol (2007) 0.92
Rasagiline in Parkinson's disease. N Engl J Med (2010) 0.92
Restoration of nigrostriatal dopamine neurons in post-MPTP treatment by the novel multifunctional brain-permeable iron chelator-monoamine oxidase inhibitor drug, M30. Neurotox Res (2009) 0.92
Iron and alpha-synuclein in the substantia nigra of MPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green tea polyphenol (-)-epigallocatechin-3-gallate. J Mol Neurosci (2004) 0.92
An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells. Neurosci Lett (2002) 0.92
Early and late gene changes in MPTP mice model of Parkinson's disease employing cDNA microarray. Neurochem Res (2002) 0.91
Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline. Br J Pharmacol (2004) 0.91
Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro. J Neurochem (2007) 0.91
Tight junction proteins expression and modulation in immune cells and multiple sclerosis. J Cell Mol Med (2012) 0.91
Neurorescue activity, APP regulation and amyloid-beta peptide reduction by novel multi-functional brain permeable iron- chelating- antioxidants, M-30 and green tea polyphenol, EGCG. Curr Alzheimer Res (2007) 0.91